ES2509892T3 - Administración de un agente para limpieza del intestino y antibiótico para el tratamiento de enfermedad intestinal - Google Patents

Administración de un agente para limpieza del intestino y antibiótico para el tratamiento de enfermedad intestinal Download PDF

Info

Publication number
ES2509892T3
ES2509892T3 ES09743658.8T ES09743658T ES2509892T3 ES 2509892 T3 ES2509892 T3 ES 2509892T3 ES 09743658 T ES09743658 T ES 09743658T ES 2509892 T3 ES2509892 T3 ES 2509892T3
Authority
ES
Spain
Prior art keywords
administration
agent
antibiotic
treatment
intestinal disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09743658.8T
Other languages
English (en)
Inventor
Lorin Johnson
William Forbes
Stephana Patton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salix Pharmaceuticals Ltd
Original Assignee
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Ltd
Application granted granted Critical
Publication of ES2509892T3 publication Critical patent/ES2509892T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso de un agente de limpieza del tracto gastrointestinal (GI) limpiador y una cantidad terapéuticamente eficaz de la rifaximina para la fabricación de un medicamento para tratar la enfermedad intestinal (EI), que comprende: administrar el agente de limpieza gastrointestinal (GI) a un sujeto en que lo necesite; y administrar la cantidad terapéuticamente eficaz de rifaximina, en el que la administración del agente de limpieza gastrointestinal (GI) está dentro de entre aproximadamente 1 a aproximadamente 90 días antes de la administración de la rifaximina.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29

Claims (1)

  1. imagen1
ES09743658.8T 2008-05-07 2009-05-07 Administración de un agente para limpieza del intestino y antibiótico para el tratamiento de enfermedad intestinal Active ES2509892T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5134108P 2008-05-07 2008-05-07
US51341P 2008-05-07
PCT/US2009/043138 WO2009137672A1 (en) 2008-05-07 2009-05-07 Methods of treating bowel disease by administering a bowel cleanser and an antibiotic

Publications (1)

Publication Number Publication Date
ES2509892T3 true ES2509892T3 (es) 2014-10-20

Family

ID=41265004

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09743658.8T Active ES2509892T3 (es) 2008-05-07 2009-05-07 Administración de un agente para limpieza del intestino y antibiótico para el tratamiento de enfermedad intestinal

Country Status (12)

Country Link
US (2) US20090324736A1 (es)
EP (1) EP2294012B1 (es)
JP (1) JP5752032B2 (es)
AU (1) AU2009244190B2 (es)
CA (1) CA2723752A1 (es)
DK (1) DK2294012T3 (es)
ES (1) ES2509892T3 (es)
HR (1) HRP20140939T1 (es)
PL (1) PL2294012T3 (es)
PT (1) PT2294012E (es)
SI (1) SI2294012T1 (es)
WO (1) WO2009137672A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
WO2008035109A1 (en) 2006-09-22 2008-03-27 Cipla Limited Rifaximin
GEP20135898B (en) 2008-02-25 2013-08-12 Salix Pharmaceuticals Ltd Rifaximin forms and usage
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US9603876B2 (en) 2008-09-25 2017-03-28 New York University Compositions and methods for restoring gastrointestinal microbiota following antibiotic treatment
KR101906177B1 (ko) 2008-12-10 2018-10-10 시플라 리미티드 리팍시민 복합체
CA2781580A1 (en) * 2009-11-23 2011-05-26 Cipla Limited Topical foam composition
US8532349B2 (en) * 2010-02-02 2013-09-10 Omnivision Technologies, Inc. Encapsulated image acquisition devices having on-board data storage, and systems, kits, and methods therefor
CA2812299C (en) * 2010-09-23 2020-08-04 Inflammagen, Llc Administration of serine protease inhibitors to the stomach
TWI535461B (zh) 2011-03-11 2016-06-01 諾金私人有限公司 結腸清潔溶液、用於製備該溶液之組成物、包含該組成物或溶液之套組、與製備該溶液之方法
US8778907B2 (en) * 2011-04-27 2014-07-15 Cumberland Pharmaceuticals Lactulose for bowel evacuation
KR102113822B1 (ko) * 2012-07-17 2020-05-22 바이엘 뉴질랜드 리미티드 주사용 항생제 제제 및 그의 이용 방법
PL3473248T3 (pl) 2012-09-11 2022-07-25 Norgine Bv Kompozycje zawierające glikol polietylenowy i siarczany metali alkalicznych lub metali ziem alkalicznych do zastosowania jako kompozycje do oczyszczania jelita grubego
CN104955457A (zh) * 2012-09-12 2015-09-30 萨利克斯药品公司 给予利福昔明而不产生抗生素耐药性的方法
HK1212555A1 (zh) * 2012-09-13 2016-06-17 Salix Pharmaceuticals, Inc. 改善患有肝性腦病的受試者的長期生存和降低其再住院率的方法
WO2014144407A1 (en) 2013-03-15 2014-09-18 Braintree Laboratories, Inc. Dual use oral pharmaceutical composition tablets of sulfate saltes and methods of use thereof
WO2014176632A1 (en) * 2013-04-30 2014-11-06 Borody Thomas J Compositions and methods for treating microbiota-related psychotropic conditions and diseases
JP2016526032A (ja) * 2013-05-17 2016-09-01 サリックス ファーマスーティカルズ，インコーポレーテッド ポジション（ｐｏｓｉｔｉｏｎ）放射断層撮影（ｐｅｔ）スキャンでリファキシミンを使用する方法
US20160120915A1 (en) * 2013-06-10 2016-05-05 New York University Methods for manipulating immune responses by altering microbiota
KR101423005B1 (ko) 2013-10-17 2014-07-28 강윤식 장 세정용 조성물
US9387199B2 (en) * 2013-11-12 2016-07-12 University Of Virginia Patent Foundation Compositions and methods for treating clostridium infection and preventing recurrence of infection
US9314442B2 (en) 2014-03-25 2016-04-19 Leading BioSciences, Inc. Compositions for the treatment of autodigestion
CA2947434A1 (en) 2014-04-29 2015-11-05 Colonaryconcepts Llc Foods, systems, methods, and kits for providing electrolyte replacement
WO2016003536A1 (en) * 2014-06-30 2016-01-07 Salix Pharmaceuticals, Inc. Methods for retreating irritable bowel syndrome (ibs)
WO2016140981A1 (en) 2015-03-02 2016-09-09 Colonaryconcepts Llc Compounds and methods for peg metabolite and peg breakdown product assays
HK1247105A1 (zh) 2015-04-02 2018-09-21 Theravance Biopharma R&D Ip, Llc Mu类鸦片受体拮抗剂与类鸦片药剂的组合剂型
KR102619907B1 (ko) * 2015-08-17 2024-01-02 서화수 가축설사 치료용 복합제 조성물
EA201891592A1 (ru) * 2016-01-08 2019-02-28 КОЛОНАРИКОНСЕПТС ЭлЭлСи Основанная на пищевых продуктах доставка терапевтического агента для лечения печеночной энцефалопатии
US10653728B2 (en) 2016-10-17 2020-05-19 New York University Probiotic compositions for improving metabolism and immunity
EP3416627B9 (en) * 2017-04-26 2020-04-22 Sandoz AG Oral dosage form comprising rifaximin in form beta
WO2019140032A1 (en) * 2018-01-11 2019-07-18 Meritage Pharma, Inc. Stable corticosteroid compositions
EP3768262A4 (en) * 2018-03-23 2021-12-15 Thomas Julius Borody COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASE OF THE INTESTINE AND DISEASES AND CONDITIONS CAUSED BY OR ASSOCIATED WITH FUSOBACTERIUM

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3363997A (en) 1958-12-22 1968-01-16 Monsanto Co Composition of matter and process
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
US4883785A (en) * 1984-07-27 1989-11-28 Chow Wing Sun Complex of anti-fungal agent and cyclodextrin and method
WO1987000754A1 (en) 1985-08-01 1987-02-12 Braintree Laboratories, Inc. Low-sodium laxative and lavage formulation
US5274001A (en) 1987-12-24 1993-12-28 Borody Thomas J Orthostatic lavage solutions
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
ES2224428T3 (es) * 1997-09-26 2005-03-01 Celltech Pharma Europe Limited Composicion farmnaceutica para el tratamiento de la enfermedad inflmatoria intestinal.
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
JP2005526059A (ja) * 2002-03-07 2005-09-02 アドバンシス ファーマスーティカル コーポレイション 抗生物質組成物
CA2496864C (en) * 2002-08-26 2009-04-28 S.L.A. Pharma Ag A pharmaceutical composition
GB0224909D0 (en) * 2002-10-25 2002-12-04 Norgine Europe Bv Colon cleansing compositions
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7687075B2 (en) * 2003-11-19 2010-03-30 Salix Pharmaceuticals, Ltd. Colonic purgative composition with soluble binding agent
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
US20090233888A1 (en) * 2005-03-23 2009-09-17 Usc Stevens, University Of Southern California Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
CA2607250C (en) * 2005-05-06 2012-11-06 Salix Pharmaceuticals, Inc. Polyethylene glycol colonic purgative composition
WO2007103448A2 (en) * 2006-03-09 2007-09-13 Salix Pharmaceuticals, Inc. Rifaximin anti-rectal dysfunction preparation
US20100069421A1 (en) * 2006-08-02 2010-03-18 Doug Bettenhausen Compositions and methods for the treatment of radiation proctosigmoitis
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
WO2009052255A2 (en) * 2007-10-17 2009-04-23 Salix Pharmaceuticals, Ltd. Novel therapeutic targets in bowel disease
CN110914703A (zh) 2017-07-31 2020-03-24 深圳市大疆创新科技有限公司 对点云中基于运动的不准确性的校正
US11960008B2 (en) 2018-05-17 2024-04-16 Cmos Sensor, Inc. Method and system for pseudo 3D mapping in robotic applications
KR102382079B1 (ko) 2020-02-11 2022-03-31 효성중공업 주식회사 에어갭 조절장치
US11963008B2 (en) 2020-11-25 2024-04-16 Truist Bank Geolocation-based notifications using relationships in separate systems

Also Published As

Publication number Publication date
US20090324736A1 (en) 2009-12-31
SI2294012T1 (sl) 2014-11-28
EP2294012A4 (en) 2011-10-26
PL2294012T3 (pl) 2014-12-31
PT2294012E (pt) 2014-10-15
CA2723752A1 (en) 2009-11-12
US20130164384A1 (en) 2013-06-27
DK2294012T3 (da) 2014-10-06
AU2009244190B2 (en) 2016-02-25
HRP20140939T1 (hr) 2014-11-21
EP2294012B1 (en) 2014-07-09
JP2011519952A (ja) 2011-07-14
JP5752032B2 (ja) 2015-07-22
HK1156293A1 (en) 2012-06-08
EP2294012A1 (en) 2011-03-16
AU2009244190A1 (en) 2009-11-12
WO2009137672A1 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
ES2509892T3 (es) Administración de un agente para limpieza del intestino y antibiótico para el tratamiento de enfermedad intestinal
CL2021000622A1 (es) Uso de niclosamida para la preparación de un medicamento para el tratamiento de colitis autoinmune, una enfermedad inflamatoria intestinal, colitis autoinmune iatrogénica, divisional de la solicitud de patente nº 559-2018.
ES2526648T3 (es) Método para mejorar el estrés oxidativo y la memoria de trabajo mediante la administración de pterostilbeno
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
CL2008001297A1 (es) N-[(1s)-1-(5-fluoropirim idin-2-i1 )etil]-3-(5-isopropoxi-1 h-pirazol-3-il )-3h-imidazo[4,5-b]piridin-5amina o una sal farmacéuticamente aceptabie del mismo; composición farmacéutica que lo comprende; y su uso en el tratamiento del cáncer.
EP2248519A3 (en) Non-mucoadhesive film dosage forms
EA200900155A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
AR070047A1 (es) Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog.
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
CL2011000099A1 (es) Uso de una beta-defensina humana en la manufactura de un medicamento que sirve para el tratamiento de una enfermedad intestinal inflamatoria.
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
EP4309722A3 (en) Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
AR062659A1 (es) Composicion de liberacion sostenida de levodopa y metodo para su uso
AR059357A1 (es) Formulaciones farmaceuticas
ES2552654T3 (es) Uso de LCAT para tratar la anemia y la disfunción de los glóbulos rojos
EA200801698A1 (ru) Лекарственные композиции для применения в вагине
AR062390A1 (es) Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas
ES2559238T3 (es) Agente para reducir el peso de la grasa visceral
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
FI20095600A7 (fi) Koostumus ihosairauksien hoitoa varten
AR117614A1 (es) Forma de dosificación farmacéutica administrable por vía oral con liberación modificada
ECSP077843A (es) Tratamiento o prevención del prurito
ES2525931T3 (es) Composiciones y métodos para prevenir o tratar enfermedad inflamatoria intestinal